Cost-effectiveness of pertuzumab in human epidermal growth factor receptor 2-positive metastatic breast cancer

Journal of Clinical Oncology

Volumn 34, Issue 9, 2016, Pages 902-909

  Durkee, Ben Y ^a   Qian, Yushen ^a   Pollom, Erqi L ^a   King, Martin T ^a   Dudley, Sara A ^a   Shaffer, Jenny L ^a   Chang, Daniel T ^a   Gibbs, Iris C ^a   Goldhaber Fiebert, Jeremy D ^a   Horst, Kathleen C ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PERTUZUMAB; TRASTUZUMAB; ANTINEOPLASTIC AGENT; ERBB2 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; TAXOID;

AGED; ARTICLE; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER SURVIVAL; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DRUG DOSE INCREASE; FEMALE; HEALTH CARE COST; HEALTH STATUS; HIDDEN MARKOV MODEL; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MEDICARE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; UNSPECIFIED SIDE EFFECT; BIOSYNTHESIS; BREAST NEOPLASMS; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DECISION SUPPORT SYSTEM; ECONOMICS; ENZYMOLOGY; MARKOV CHAIN; MIDDLE AGED; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; STATISTICAL MODEL; TUMOR INVASION; UNITED STATES;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; FEMALE; HUMANS; MARKOV CHAINS; MIDDLE AGED; MODELS, ECONOMIC; NEOPLASM INVASIVENESS; RECEPTOR, ERBB-2; TAXOIDS; TRASTUZUMAB; UNITED STATES;

EID: 84962091515     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.62.9105     Document Type: Article

References (47)

1. Owens MA, Horten BC, Da Silva MM: HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer 5:63-69, 2004
2. Yaziji H, Goldstein L, Barry T, et al: HER-2 testing in breast cancer using parallel tissue-based methods. JAMA 291:1972-1977, 2004
3. Dawood S, Broglio K, Buzdar AU, et al: Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: An institutional-based review. J Clin Oncol 28:92-98, 2010
4. Slamon DJ, Leyland-Jones B, Shak S, et al: Use of Chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792, 2001
5. Marty M, Cognetti F, Maraninchi D, et al: Randomized phaseII trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: The M77001 Study Group. J Clin Oncol 23:4265-4274, 2005
6. Tzahar E, Waterman H, Chen X, et al: A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol 16:5276-5287, 1996
7. Harbeck N, Beckmann MW, Rody A, et al: HER2 Dimerization inhibitor pertuzumab: Mode of action and clinical data in breast cancer. Breast Care (Basel) 8:49-55, 2013
8. Baselga J, Cortés J, Kim SB, et al: Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 366:109-119, 2012
9. Swain SM, Baselga J, Kim SB, et al: Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med 372:724-734, 2015
10. Schneeweiss A, Chia S, Hickish T, et al: Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: A randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol 24:2278-2284, 2013
11. Gianni L, Pienkowski T, Im YH, et al: Efficacy and safety of neoadjuvant pertuzumab and trastuzumabinwomen with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): A randomised multicentre, open-label, phase 2 trial. Lancet Oncol 13:25-32, 2012
12. Dartmouth Institute for Health Policy Clinical Practice, Center for Health Policy Research: Percent of Cancer Patients Enrolled in Hospice, by Interval Before Death, The Dartmouth Atlas of Health Care, 2010. http://www.dartmouthatlas.org
13. Christakis NA, Escarce JJ: Survival of Medicare patients after enrollment in hospice programs. N Engl J Med 335:172-178, 1996
14. Younis T, Milch R, Abul-Khoudoud N, et al: Length of survival of patients with cancer in hospice: A retrospective analysis of patients treated at a major cancer center versus other practice settings. J Palliative Med 10:381-389, 2007
15. Swain SM, Kim SB, Cortés J, et al: Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 14:461-471, 2013
16. Arias E: United States life tables, 2010. Natl Vital Stat Rep 63:1-63, 2014
17. Hedden L, O'Reilly S, Lohrisch C, et al: Assessing the real-world cost-effectiveness of adjuvant trastuzumab in HER-2/neu positive breast cancer. Oncologist 17:164-171, 2012
18. Attard CL, Pepper AN, Brown ST, et al: Cost-effectiveness analysis of neoadjuvant pertuzumab and trastuzumab therapy for locally advanced, inflammatory, or early HER2-positive breast cancer in Canada. J Med Econ 18:173-188, 2015
19. Casarett D, Fishman J, O'Dwyer PJ, et al: How should we design supportive cancer care? The patient's perspective. J Clin Oncol 26:1296-1301, 2008
20. Launois R, Reboul-Marty J, Henry B, et al: A cost-utility analysis of second-line chemotherapy in metastatic breast cancer: Docetaxel versus paclitaxel versus vinorelbine. Pharmacoeconomics 10: 504-521, 1996
21. Mariotto AB, Yabroff KR, Shao Y, et al: Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst 103:117-128, 2011
22. Chastek B, Harley C, Kallich J, et al: Health care costs for patients with cancer at the end of life. J Oncol Pract 8:75s-80s, 2012
23. Zhang B, Wright AA, Huskamp HA, et al: Health care costs in the last week of life: Associations with end-of-life conversations. Arch Intern Med 169:480-488, 2009
24. Hansen RN, Ramsey SD, Lalla D, et al: Identification and cost of adverse events in metastatic breast cancer in taxane and capecitabine based regimens. Springerplus 3:259 2014
25. Eddy DM, Hollingworth W, Caro JJ, et al: Model transparency and validation: A report of the ISPOR-SMDM Modeling Good Research Practices Task Force-7. Med Decis Making 32:733-743, 2012
26. Gold MR, Siegel JE, Russell LB, et al: Cost-effectiveness in health and medicine. New York, NY, Oxford University Press, 1996
27. Briggs AH, Weinstein MC, Fenwick EAL, et al: Model parameter estimation and uncertainty analysis: A report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group-6. Med Decis Making 32:722-732, 2012
28. Doubilet P, Begg CB, Weinstein MC, et al: Probabilistic sensitivity analysis using Monte Carlo simulation: A practical approach. Med Decis Making 5:157-177, 1985
29. Centers for Medicare and Medicaid Services: Medicare Part B Drug Average Sale Price. http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Part-B-Drugs/McrPartBDrugAvgSalesPrice/index.html
30. Centers for Medicare and Medicaid Services: Medicare Physician Fee Schedule 2014. https://www.cms.gov/apps/physician-fee-schedule/
31. Hutton J, Brown R, Borowitz M, et al: A new decision model for cost-utility comparisons of chemotherapy in recurrent metastatic breast cancer. Pharmacoeconomics 9:8-22, 1996 (suppl 2)
32. Hillner BE, Smith TJ, Desch CE: Efficacy and cost-effectiveness of autologous bone marrow transplantation in metastatic breast cancer: Estimates using decision analysis while awaiting clinical trial results. JAMA 267:2055-2061, 1992
33. US Department of Labor: Inflation & Prices Online Calculator: Bureau of Labor Statistics, 2015. http://www.bls.gov/data/#calculators
34. Briggs AH, Gray AM: Handling uncertainty in economic evaluations of healthcare interventions. BMJ 319:635-638, 1999
35. National Cancer Institute: Surveillance, Epidemiology, and End Results (SEER) Program Research Data 1973-2011, 2014. www.seer.cancer.gov
36. O'Shaughnessy J: Extending survival with chemotherapy in metastatic breast cancer. Oncologist 10:20-29, 2005
37. Fleeman N, Bagust A, Beale S, et al: Pertu-zumab in combination with trastuzumab and docetaxel for the treatment of HER2-positive metastatic or locally recurrent unresectable breast cancer. Pharmacoeconomics 33:13-23, 2015
38. National Centre for Pharmacoeconomics: Cost effectiveness of pertuzumab (perjeta) in combination with trastuzumab and docetaxel in adults with HER2-positive metastatic or locally recurrent unresectable breast cancer who have not received previous anti-HER2 Therapy or chemotherapy. National Centre for Pharmacoeconomics, Rialto Gate, St. James's Hospital, Dublin 8, Ireland, 2013
39. Cortés J, Baselga J, Im YH, et al: Health-related quality-of-life assessment in CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer. Ann Oncol 24:2630-2635, 2013
40. Ubel PA, Hirth RA, Chernew ME, et al: What is the price of life and why doesn't it increase at the rate of inflation? Arch Intern Med 163:1637-1641, 2003
41. Liberato NL, Marchetti M, Barosi G: Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 25:625-633, 2007
42. Kurian AW, Thompson RN, Gaw AF, et al: A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancer. J Clin Oncol 25:634-641, 2007
43. Elkin EB, Weinstein MC, Winer EP, et al: HER-2 testing and trastuzumab therapy for metastatic breast cancer: A cost-effectiveness analysis. J Clin Oncol 22:854-863, 2004
44. Tosteson ANA, Stout NK, Fryback DG, et al: Cost-effectiveness of digital mammography breast cancer screening. Ann Intern Med 148:1-10, 2008
45. Zbrozek AS, Cantor SB, Cardenas MP, et al: Pharmacoeconomic analysis of ondansetron versus metoclopramide for cisplatin-induced nausea and vomiting. Am J Hosp Pharm 51:1555-1563, 1994
46. Murphy JD, Chang DT, Abelson J, et al: Cost-effectiveness of modern radiotherapy techniques in locally advanced pancreatic cancer. Cancer 118: 1119-1129, 2012
47. Kaiser Family Foundation: Contribution to total health expenditures by individuals: Analysis of medical expenditure panel survey. Agency for Healthcare Research and Quality, US Department of Health and Human Services, 2012